FFA2 activation combined with ulcerogenic COX inhibition induces duodenal mucosal injury via the 5-HT pathway in rats

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 313, Issue 2, 2017, Pages G117-G128

  Akiba, Yasutada ^a,b,d   Maruta, Koji ^b   Narimatsu, Kazuyuki ^b   Said, Hyder ^b   Kaji, Izumi ^a,b,d   Kuri, Ayaka ^e   Iwamoto, Ken Ichi ^e   Kuwahara, Atsukazu ^e   Kaunitz, Jonathan D ^a,b,c,d  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Brentwood Biomedical Research Institute Los Angeles   (United States)

^e UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Bicarbonate secretion; Cyclooxygenase; Free fatty acid receptor 2; Nonsteroidal anti inflammatory drug induced enteropathy; Serotonin; Short chain fatty acids

Indexed keywords

4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 3 PIPERIDINOPROPYL ESTER; 4 [[[1 (BENZO[B]THIEN 3 YLCARBONYL) 2 METHYL 2 AZETIDINYL]CARBONYL][(3 CHLOROPHENYL)METHYL]AMINO]BUTANOIC ACID; ACETANILIDE; ATROPINE; BICARBONATE; FATTY ACID; FATTY ACID SYNTHASE INHIBITOR; FREE FATTY ACID RECEPTOR 2; INDOMETACIN; OMEPRAZOLE; ONDANSETRON; PHENYLACETAMIDE 1; PROSTAGLANDIN SYNTHASE; SEROTONIN; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DUODENAL EROSION; DUODENAL MUCOSAL INJURY; DUODENUM INJURY; DUODENUM MUCOSA; DUODENUM ULCER; ENTEROPATHY; ENZYME ACTIVATION; EPIGASTRIC PAIN; EROSION; FOREGUT; HEPATIC PORTAL VEIN; HYPEREMIA; IN VIVO STUDY; INTESTINE BLOOD FLOW; INTESTINE INJURY; INTESTINE ULCER; LASER DOPPLER FLOWMETRY; MALE; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SEROTONIN RELEASE; STOMACH ACID; VOMITING; AGONISTS; ANIMAL; DRUG EFFECTS; DUODENUM; ENTEROCHROMAFFIN CELL; INTESTINE MUCOSA; METABOLISM;

ANIMALS; BICARBONATES; CYCLOOXYGENASE INHIBITORS; DUODENUM; ENTEROCHROMAFFIN CELLS; INDOMETHACIN; INTESTINAL MUCOSA; RATS; RECEPTORS, G-PROTEIN-COUPLED; SEROTONIN;

EID: 85026812715     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00041.2017     Document Type: Article

References (68)

1. Akiba Y, Guth PH, Engel E, Nastaskin I, Kaunitz JD. Acid-sensing pathways of rat duodenum. Am J Physiol Gastrointest Liver Physiol 277: G268–G274, 1999.
2. Akiba Y, Inoue T, Kaji I, Higashiyama M, Narimatsu K, Iwamoto K, Watanabe M, Guth PH, Engel E, Kuwahara A, Kaunitz JD. Shortchain fatty acid sensing in rat duodenum. J Physiol 593: 585–599, 2015. doi:10.1113/jphysiol.2014.280792.
3. Akiba Y, Kaunitz JD. Duodenal luminal chemosensing; acid, ATP, and nutrients. Curr Pharm Des 20: 2760–2765, 2014. doi:10.2174/13816128113199990565.
4. Akiba Y, Watanabe C, Mizumori M, Kaunitz JD. Luminal L-glutamate enhances duodenal mucosal defense mechanisms via multiple glutamate receptors in rats. Am J Physiol Gastrointest Liver Physiol 297: G781–G791, 2009. doi:10.1152/ajpgi.90605.2008.
5. Andrews PL. Physiology of nausea and vomiting. Br J Anaesth 69, Suppl 1: 2S–19S, 1992. doi:10.1093/bja/69.supplement_1.2S.
6. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130: 34–43, 2006. doi:10.1053/j.gastro.2005.09.031.
7. Barnes NM, Costall B, Naylor RJ, Tattersall FD. Identification of 5-HT3 recognition sites in the ferret area postrema. J Pharm Pharmacol 40: 586–588, 1988. doi:10.1111/j.2042-7158.1988.tb05312.x.
8. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 42: 42–46, 1998. doi:10.1136/gut.42.1.42.
9. Beattie DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 377: 181–203, 2008. doi:10.1007/s00210-008-0276-9.
10. Bharucha AE, Camilleri M, Burton DD, Thieke SL, Feuerhak KJ, Basu A, Zinsmeister AR. Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia. Am J Gastroenterol 109: 1910–1920, 2014. doi:10.1038/ajg.2014.330.
11. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Simrén M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149: 1399–1407.e2, 2015. doi:10.1053/j.gastro.2015.07.054.
12. Botta GA, Radin L, Costa A, Schito G, Blasi G. Gas-liquid chromatography of the gingival fluid as an aid in periodontal diagnosis. J Periodontal Res 20: 450–457, 1985. doi:10.1111/j.1600-0765.1985.tb00827.x.
13. Braun T, Voland P, Kunz L, Prinz C, Gratzl M. Enterochromaffin cells of the human gut: sensors for spices and odorants. Gastroenterology 132: 1890–1901, 2007. doi:10.1053/j.gastro.2007.02.036.
14. Cho HJ, Callaghan B, Bron R, Bravo DM, Furness JB. Identification of enteroendocrine cells that express TRPA1 channels in the mouse intestine. Cell Tissue Res 356: 77–82, 2014. doi:10.1007/s00441-013-1780-x.
15. Coleman NS, Foley S, Dunlop SP, Wheatcroft J, Blackshaw E, Perkins AC, Singh G, Marsden CA, Holmes GK, Spiller RC. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 4: 874–881, 2006. doi:10.1016/j.cgh.2006.04.017.
16. Costa MB, Azeredo IL Jr, Marciano RD, Caldeira LM, Bafutto M. Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test. Arq Gastroenterol 49: 279–283, 2012. doi:10.1590/S0004-28032012000400009.
17. Cubeddu LX. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53, Suppl 1: 18–25, 1996. doi:10.1159/000227636.
18. D’Almeida MS, Gaudin C, Lebrec D. Validation of 1- and 2-mm transit-time ultrasound flow probes on mesenteric artery and aorta of rats. Am J Physiol Heart Circ Physiol 268: H1368–H1372, 1995.
19. Eglen RM, Bley K, Bonhaus DW, Clark RD, Hegde SS, Johnson LG, Leung E, Wong EH. RS 23597-190: a potent and selective 5-HT4 receptor antagonist. Br J Pharmacol 110: 119–126, 1993. doi:10.1111/j.1476-5381.1993.tb13780.x.
20. Eliakim R, Ophir M, Rachmilewitz D. Duodenal mucosal injury with nonsteroidal antiinflammatory drugs. J Clin Gastroenterol 9: 395–399, 1987. doi:10.1097/00004836-198708000-00008.
21. Fujimiya M, Okumiya K, Kuwahara A. Immunoelectron microscopic study of the luminal release of serotonin from rat enterochromaffin cells induced by high intraluminal pressure. Histochem Cell Biol 108: 105–113, 1997. doi:10.1007/s004180050151.
22. Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology 150: 358–66.e8, 2016. doi:10.1053/j.gastro.2015.10.047.
23. Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, Eubanks S, Harris M, Pappas TN, Takahashi T. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 284: R1269–R1276, 2003. doi:10.1152/ajpregu.00442.2002.
24. Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63: 1617–1625, 2014. doi:10.1136/gutjnl-2013-305989.
25. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397–414, 2007. doi:10.1053/j.gastro.2006.11.002.
26. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol 20: 2482–2491, 2014. doi:10.3748/wjg.v20.i10.2482.
27. Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol 28: 281–289, 2016. doi:10.1097/MEG.0000000000000557.
28. Glisić R, Koko V, Todorović V, Drndarević N, Cvijić G. Serotoninproducing enterochromaffin (EC) cells of gastrointestinal mucosa in dexamethasone- treated rats. Regul Pept 136: 30–39, 2006. doi:10.1016/j.regpep.2006.04.019.
29. Hagbom M, Istrate C, Engblom D, Karlsson T, Rodriguez-Diaz J, Buesa J, Taylor JA, Loitto VM, Magnusson KE, Ahlman H, Lundgren O, Svensson L. Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting. PLoS Pathog 7: e1002115, 2011. doi:10.1371/journal.ppat.1002115.
30. Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, Gathright GR, Yates BJ, Andrews PL. Why can’t rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS One 8: e60537, 2013. doi:10.1371/journal.pone.0060537.
31. Høverstad T, Bjørneklett A, Fausa O, Midtvedt T. Short-chain fatty acids in the small-bowel bacterial overgrowth syndrome. Scand J Gastroenterol 20: 492–499, 1985. doi:10.3109/00365528509089686.
32. Høverstad T, Bjørneklett A, Midtvedt T, Fausa O, Bøhmer T. Shortchain fatty acids in the proximal gastrointestinal tract of healthy subjects. Scand J Gastroenterol 19: 1053–1058, 1984.
33. Inoue T, Higashiyama M, Kaji I, Rudenkyy S, Higuchi K, Guth PH, Engel E, Kaunitz JD, Akiba Y. Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats. Dig Dis Sci 59: 1286–1295, 2014. doi:10.1007/s10620-013-3001-6.
34. Iwai T, Ichikawa T, Kida M, Goso Y, Saegusa Y, Okayasu I, Saigenji K, Ishihara K. Vulnerable sites and changes in mucin in the rat small intestine after non-steroidal anti-inflammatory drugs administration. Dig Dis Sci 55: 3369–3376, 2010. doi:10.1007/s10620-010-1185-6.
35. Kaji I, Iwanaga T, Watanabe M, Guth PH, Engel E, Kaunitz JD, Akiba Y. SCFA transport in rat duodenum. Am J Physiol Gastrointest Liver Physiol 308: G188–G197, 2015. doi:10.1152/ajpgi.00298.2014.
36. Kaji I, Karaki S, Tanaka R, Kuwahara A. Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol 42: 27–38, 2011. doi:10.1007/s10735-010-9304-4.
37. Karaki S, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, Suzuki Y, Kuwahara A. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J Mol Histol 39: 135–142, 2008. doi:10.1007/s10735-007-9145-y.
38. Kato S, Matsuda N, Matsumoto K, Wada M, Onimaru N, Yasuda M, Amagase K, Horie S, Takeuchi K. Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: proulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors. Pharmacol Res 66: 226–234, 2012. doi:10.1016/j.phrs.2012.06.002.
39. Kaunitz JD, Akiba Y. Acid-sensing protective mechanisms of duodenum. J Physiol Pharmacol 54, Suppl 4: 19–26, 2003.
40. Kellum J, McCabe M, Schneier J, Donowitz M. Neural control of acid-induced serotonin release from rabbit duodenum. Am J Physiol Gastrointest Liver Physiol 245: G824–G831, 1983.
41. Kellum JM, Albuquerque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release and Cl- secretion via afferent neurons and 5-HT4 receptors. Am J Physiol Gastrointest Liver Physiol 277: G515–G520, 1999.
42. Kellum JM, Donowitz M, Cerel A, Wu J. Acid and isoproterenol cause serotonin release by acting on opposite surfaces of duodenal mucosa. J Surg Res 36: 172–176, 1984. doi:10.1016/0022-4804(84)90084-2.
43. Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil 16: 251–257, 2010. doi:10.5056/jnm.2010.16.3.251.
44. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, Jaeckel P, Ge H, Wang Y, Jiao X, Liu J, Kayser F, Tian H, Li Y. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol 74: 1599–1609, 2008. doi:10.1124/mol.108.049536.
45. Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, Saito H, Yoshioka M. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther 99: 149–165, 2003. doi:10.1016/S0163-7258(03)00057-3.
46. Mizumori M, Meyerowitz J, Takeuchi T, Lim S, Lee P, Supuran CT, Guth PH, Engel E, Kaunitz JD, Akiba Y. Epithelial carbonic anhydrases facilitate PCO2 and pH regulation in rat duodenal mucosa. J Physiol 573: 827–842, 2006. doi:10.1113/jphysiol.2006.107581.
47. Munck LK, Mertz-Nielsen A, Westh H, Bukhave K, Beubler E, Rask-Madsen J. Prostaglandin E2 is a mediator of 5-hydroxytryptamine induced water and electrolyte secretion in the human jejunum. Gut 29: 1337–1341, 1988. doi:10.1136/gut.29.10.1337.
48. Nzakizwanayo J, Dedi C, Standen G, Macfarlane WM, Patel BA, Jones BV. Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance. Sci Rep 5: 17324, 2015. doi:10.1038/srep17324.
49. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: 3503–3506, 2000. doi:10.1111/j.1572-0241.2000.03368.x.
50. Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E, Delerive P, Deprez P, De Vos S, Djata F, Fletcher S, Kopiejewski S, L’Ebraly C, Lefrançois JM, Lavazais S, Manioc M, Nelles L, Oste L, Polancec D, Quénéhen V, Soulas F, Triballeau N, van der Aar EM, Vandeghinste N, Wakselman E, Brys R, Saniere L. Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem 57: 10044–10057, 2014. doi:10.1021/jm5012885.
51. Reigstad CS, Salmonson CE, Rainey JF III, Szurszewski JH, Linden DR, Sonnenburg JL, Farrugia G, Kashyap PC. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 29: 1395–1403, 2015. doi:10.1096/fj.14-259598.
52. Roth KA, Kim S, Gordon JI. Immunocytochemical studies suggest two pathways for enteroendocrine cell differentiation in the colon. Am J Physiol Gastrointest Liver Physiol 263: G174–G180, 1992.
53. Satoh H, Amagase K, Ebara S, Akiba Y, Takeuchi K. Cyclooxygenase (COX)-1 and COX-2 both play an important role in the protection of the duodenal mucosa in cats. J Pharmacol Exp Ther 344: 189–195, 2013. doi:10.1124/jpet.112.199182.
54. Satoh H, Amagase K, Takeuchi K. Exacerbation of nonsteroidal antiinflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 343: 270–277, 2012. doi:10.1124/jpet.112.197475.
55. Shimizu K, Koga H, Iida M, Haruma K. Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats. Dig Dis Sci 52: 3019–3028, 2007. doi:10.1007/s10620-007-9804-6.
56. Sjölund K, Sandén G, Håkanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 85: 1120–1130, 1983.
57. Spiller R. Serotonin and GI clinical disorders. Neuropharmacology 55: 1072–1080, 2008. doi:10.1016/j.neuropharm.2008.07.016.
58. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 66: 30–41, 2002. doi:10.1159/000064419.
59. Takeuchi K, Ohuchi T, Matsumoto J, Okabe S. Regulation of gastroduodenal bicarbonate secretion by capsaicin-sensitive sensory neurons in rats. J Clin Gastroenterol 17, Suppl 1: S33–S39, 1993. doi:10.1097/00004836-199312001-00009.
60. Tsukamoto Y, Goto H, Hase S, Arisawa T, Ohara A, Suzuki T, Hoshino H. Serotonin-induced decrease of duodenal mucosal blood flow plus acid load produces duodenal mucosal lesion in rats. Digestion 50: 99–103, 1991. doi:10.1159/000200746.
61. Turvill JL, Connor P, Farthing MJ. The inhibition of cholera toxininduced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br J Pharmacol 130: 1031–1036, 2000. doi:10.1038/sj.bjp.0703414.
62. Unmack MA, Hansen MB, Grondahl ML, Olsen JE, Christensen P, Skadhauge E. Effects of indomethacin on Salmonella typhimurium- and cholera toxin-induced fluid accumulation in the porcine small intestine. J Vet Med A Physiol Pathol Clin Med 48: 153–163, 2001. doi:10.1046/j.1439-0442.2001.00348.x.
63. van Boxel OS, ter Linde JJ, Siersema PD, Smout AJ. Role of chemical stimulation of the duodenum in dyspeptic symptom generation. Am J Gastroenterol 105: 803–811, 2010. doi:10.1038/ajg.2010.100.
64. von der Ohe MR, Camilleri M, Kvols LK. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 106: 1184–1189, 1994. doi:10.1016/0016-5085(94)90008-6.
65. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314–1322, 2011. doi:10.1053/j.gastro.2011.06.075.
66. Wang JH, Inoue T, Higashiyama M, Guth PH, Engel E, Kaunitz JD, Akiba Y. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats. J Pharmacol Exp Ther 339: 464–473, 2011. doi:10.1124/jpet.111.184788.
67. Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev 64: 359–388, 2012. doi:10.1124/pr.111.004697.
68. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161: 264–276, 2015. doi:10.1016/j.cell.2015.02.047.